Beyond PD-1/PD-L1: TME-Targeted Therapies in the Era of Immunotherapy Resistance. (2026). Journal of Biomolecules, Pathogenesis and Therapeutics, 2(1), 1-3. https://doi.org/10.68041/jbpt.v2i1/06